What is Eton Pharmaceuticals's gross profit margin?

What is the market's earnings forecast for Eton Pharmaceuticals next quarter?

What is the revenue and EPS growth rate for Eton Pharmaceuticals year over year?

What guidance did Eton Pharmaceuticals's management provide for the next earnings period?

What factors drove the changes in Eton Pharmaceuticals's revenue and profit?

What were the key takeaways from Eton Pharmaceuticals's earnings call?

Did Eton Pharmaceuticals beat or miss consensus estimates last quarter?

What is Eton Pharmaceuticals's latest dividend and current dividend yield?

- **Revenue Surge**: Q4 2025 revenue up 83% YoY to $21.3M, driven by new product launches and Alkindi Sprinkle growth.
- **Profit Margin Expansion**: Adjusted EBITDA margin 29% (vs. 18% prior year), with 2026 guidance for >30% margin.
- **Strategic Acquisitions**: $14M HEMANGEOL acquisition to be accretive, targeting $50M+ sales by 2027.
- **Innovation Pipeline**: Desmoda and ET-700 (extended-release Galzin) poised for rapid adoption, with peak sales potential exceeding $100M.
- **Long-Term Ambition**: $200M+ revenue by end-2027, 50% EBITDA margin by 2028, and $500M+ revenue by 2030.

**【CEO Summary Section】**
- **Revenue Growth**: Q4 2025 revenue reached $21.3 million, up 83% YoY, driven by new product launches (Increlex, Galzin, Khindivi) and strong performance of Alkindi Sprinkle.
- **Profitability**: Adjusted EBITDA margin improved to 29% (vs. 18% prior year), with GAAP net income of $1.5 million and non-GAAP net income of $5.4 million.
- **Product Launches**: Desmoda (FDA-approved oral liquid Desmopressin) launched in Q4 with strong early traction, targeting $30-50 million peak sales. HEMANGEOL acquisition ($14M) completed in Q4, expected to be a major growth driver in 2027.
- **Long-Term Goals**: 
  - 10+ commercial products achieved (13+ by 2027)
  - $200M revenue run rate by end-2027
  - 50% adjusted EBITDA margin by 2028
  - $500M revenue by 2030 through organic growth and acquisitions.

**【CFO Financial Commentary】**
- **Revenue Mix**: U.S. product sales grew 8% QoQ, with HEMANGEOL and Desmoda expected to contribute >70% gross margin.
- **Cost Management**: Adjusted gross profit margin improved to 73% (vs. 59% prior year), driven by manufacturing efficiencies.
- **Cash Flow**: Ended Q4 with $25.9M cash, despite $11.6M operating outflow due to Medicaid rebates and inventory payments.
- **2026 Outlook**: >$110M revenue, >30% adjusted EBITDA margin, and positive operating cash flow.

**【Q&A Key Highlights】**
- **HEMANGEOL Growth**: CEO expects rapid adoption due to 0% co-pay program and rare disease infrastructure. Q4 2025 sales of $12M could grow to >$50M by 2027.
- **Desmoda Launch**: 97% of initial scripts from existing pediatric endocrinology network, with adult pilot program showing early interest.
- **Cash Flow Conversion**: CFO projects 2026 operating cash flow to exceed EBITDA, excluding one-time Increlex distribution costs.
- **Pipeline Progress**: ET-700 (extended-release Galzin) PET study begins Q2, with potential $100M+ peak sales if approved.


Eton Pharmaceuticals, Inc.(ETON)-20260320-2025 Q4 Earnings call transcript

- **118% Revenue Surge**: Q3 revenue at $22.5M, driven by rare disease treatments.
- **70% Gross Margin Target**: 2025 Q4 guidance with rare disease focus.
- **5x Market Expansion**: INCRELEX label harmonization for 2026 growth.
- **FDA Pipeline Momentum**: ET-600 PDUFA in Feb 2026, ET-700 study launch.

**【CEO Summary Section】**
- **Record Revenue Growth**: Q3 revenue increased 118% year-over-year to $22.5 million, driven by INCRELEX, ALKINDI, and GALZIN launches.
- **Strategic Focus on Rare Diseases**: Emphasis on early diagnosis to extend treatment duration, with INCRELEX targeting 5x market expansion via FDA label harmonization.
- **Pipeline Momentum**: ET-700 study initiation for extended-release GALZIN and KHINDIVI label expansion; ET-600 FDA submission with PDUFA date in February 2026.

**【CFO Financial Commentary】**
- **Adjusted Gross Margin Guidance**: Targeting 70% by Q4 2025, up from 45% Q3, through higher-margin product mix (ALKINDI, INCRELEX, GALZIN).
- **Cost Control**: Sequential SG&A decline and $12 million Q3 operating cash flow despite ex-U.S. INCRELEX transition costs.
- **Long-Term Margin Vision**: 75%+ gross margin by 2028 via rare disease focus and label expansions.

**【Q&A Key Highlights】**
- **INCRELEX Label Expansion**: FDA feedback expected by end-2025 for -2 to -3 SD harmonization, targeting 5x U.S. patient base.
- **Gross Margin Cadence**: 70%+ achievable by 2028 through higher-margin product mix and reduced ex-U.S. costs.
- **Pricing Strategy**: No government pressure on rare disease pricing; focus on early diagnosis to extend treatment duration.
- **2026 Outlook**: ALKINDI, INCRELEX, GALZIN, and KHINDIVI growth with potential acquisitions in ultra-rare diseases.

Eton Pharmaceuticals, Inc. (ETON) Q3 2025 Earnings Call Transcript

- **Revenue Growth Record**: Q2 2025 revenue of $18.9 million (+108% YoY), with $80 million annual run rate expected in Q3 (3 months ahead of plan). 
- **Product Wins**: 
  - Increlex hits 100 patients 5 months early, targeting 110 by year-end. 
  - Khindivi launched with 5+ year label, aiming for <5 expansion in 2026. 
  - Galzin reaches 200 patients by year-end with $0 co-pay program. 
- **Pipeline Momentum**: ET-600 NDA accepted (PDUFA Feb 2026), ET-700 in Phase II for extended-release Galzin. 
- **Financial Strength**: $30 million cash, $8 million operating cash flow, and 75%+ long-term gross margin target. 
- **Strategic Growth**: Disciplined M&A with ultra-rare disease focus, $30 million+ available for acquisitions.

**【CEO Summary Section】**
- **Record Q2 Revenue Growth**: $18.9 million (108% YoY), driven by Increlex, Galzin, and Alkindi Sprinkle. Exceeding guidance, the company now expects to reach an $80 million annual revenue run rate in Q3 2025, 3 months ahead of schedule.
- **Product Launch Success**: 
  - **Increlex**: Reached 100 active patients 5 months ahead of schedule (target for end-2025). New goal: 110 patients by year-end, with long-term potential for 185 patients ($50-60 million annual sales). 
  - **Khindivi**: FDA-approved oral hydrocortisone solution launched in May, with plans to expand label to infants <5 years via revised formulation submission in Q1 2026. 
  - **Galzin**: Addressing Wilson disease access barriers, now available through Eton Cares with $0 co-pay. Aiming for 200 active patients by year-end. 
- **Pipeline Progress**: 
  - **ET-600**: NDA accepted with PDUFA date of Feb 25, 2026. If approved, would be the only oral liquid desmopressin for diabetes insipidus, targeting pediatric patients. 
  - **ET-700**: Extended-release Galzin in Phase II, targeting 800 U.S. patients on zinc therapy. 
- **Strategic Acquisitions**: $30 million cash on hand for disciplined, value-creating acquisitions in ultra-rare diseases. 
- **Profitability**: Generated $8 million operating cash flow and $3.1 million adjusted EBITDA, with margin expansion expected as revenue grows.

**【CFO Financial Commentary】**
- **Revenue**: $18.9 million (108% YoY), entirely from product sales. Adjusted gross margin improved to 75% (vs. 65% YoY), driven by higher-margin Alkindi and Increlex. 
- **Expenses**: 
  - R&D: $3.7 million (includes $2.2 million ET-600 NDA fee). 
  - SG&A: $9.7 million (flat to slightly down in H2 as launch costs subside). 
- **Cash Flow**: $8 million operating cash flow, with $30 million cash on hand post-Q2 (including $4.6 million from Esteve). 
- **Financial Outlook**: Full-year 2025 adjusted gross margin ~70%, targeting 75% by 2028. Non-GAAP net income of $1.5 million for Q2.

**【Q&A Key Highlights】**
- **Khindivi Adoption**: Physicians converting 5+ year patients from compounded products to Khindivi. Launch additive to Alkindi, with combined franchise >500 active patients. Expanded label for <5 years expected by end-2026. 
- **Increlex Expansion**: FDA feedback supports open-label IND for patients -2 to -3 SD IGF-1 (European standard). Potential $300 million annual market if U.S. definition harmonizes with EU. 
- **Operational Efficiency**: SG&A expenses to remain flat or decline in H2, with $30 million+ cash for acquisitions. 
- **ET-600 Launch Prep**: Commercial activities underway for Q1 2026 launch, leveraging existing pediatric endocrinology network.

Eton Pharmaceuticals, Inc. (ETON) Q2 2025 Earnings Call Transcript

- **Revenue Surge**: Q1 2025 revenue up 117% to $17.3M, driven by Alkindi (76% growth) and Increlex patient expansion (90+ vs. 67 at acquisition).
- **Pipeline Breakthroughs**: ET-400 PDUFA on May 28; ET-600 NDA filed with 10-month review; ET-700 NDA in 2027 for extended-release Galzin.
- **Margin Expansion**: Adjusted gross margin 69.5% (vs. 65.6% YoY), targeting >75% by 2028.
- **Patient Growth**: Alkindi near 500 patients; Increlex on track for 100+ by year-end; Galzin conversion >800 patients.
- **Tariff Resilience**: <1% revenue exposed to EU tariffs; no impact from Most Favored Nation policy.

**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue reached $17.3M, up 117% YoY, driven by Alkindi Sprinkle and Increlex. Product sales grew 76% to $14.0M.
- **Pipeline Momentum**: ET-400 (liquid hydrocortisone) PDUFA date is May 28, 2025; ET-600 (desmopressin oral solution) NDA filed in April with 10-month review. 
- **Margin Expansion**: Adjusted gross margin improved to 69.5% (vs. 65.6% YoY), with long-term target >75% by 2028.
- **Patient Growth**: Alkindi active patients near 500 (up from 67 in Q4 2024); Increlex patients reached 90 (vs. 67 at acquisition) with target 100+ by year-end.

**【CFO Financial Commentary】**
- **Net Loss**: $1.6M for Q1 vs. $0.8M YoY, driven by $9.2M G&A (up 77%) for commercial scale-up.
- **Cash Flow**: $2.1M operating cash flow; $17.4M cash on hand.
- **Tariff Impact**: <1% of revenue exposed to EU tariffs, minimal impact on gross margin.

**【Key Pipeline Updates】**
- **ET-400**: On track for June launch post-PDUFA; expects Q3/Q4 revenue with $100M+ peak potential.
- **ET-700**: Extended-release Galzin NDA in 2027; addresses dosing burden and GI side effects.
- **Amglidia**: FDA meeting in April validated PK study pathway for neonatal diabetes treatment.

**【Q&A Highlights】**
- **Increlex Label Expansion**: FDA meeting scheduled for July; EU label harmonization could expand U.S. patient pool to 1,000+.
- **Galzin Adoption**: Zero co-pay program driving >800 patients to switch from OTC zinc; Q3 conversion completion expected.
- **Tariff Policy**: Minimal impact due to U.S.-manufactured pipeline; no dual pricing exposure to Most Favored Nation policy.


Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: Q4 2024 revenue up 59% YoY to $11.6M, driven by organic growth and acquisitions.
- **Key Acquisitions**: Increlex and Galzin expected to contribute $55M+ and $50M+ annually.
- **Pipeline Momentum**: ET-400 NDA pending, ET-600 submission in 2025, and ET-800 targeting $100M+ hospital market.
- **Gross Margin Expansion**: 2025 adjusted gross margin to ~70%, up from 60% in 2024.
- **Patient-Centric Strategy**: Eton Cares program ensures 0 co-pay and streamlined access for all products.


**【CEO Opening Remarks】**
- Eton aims to be a leading ultra-rare disease company, focusing on unmet needs in conditions with fewer than 10,000 patients in the U.S.
- Strategic pillars: organic growth of existing products, internal pipeline development, and external acquisitions.
- 2024 revenue reached $39M, up from $3M in 2021; targeting $100M+ in near term with acquisitions of Increlex, Galzin, and ET-400.

**【CFO Financial Overview】**
- Q4 2024 revenue: $11.6M (YoY +59%), driven by Carglumic Acid and ALKINDI SPRINKLE.
- Gross profit: $8.9M (YoY +78%), despite stepped-up inventory costs.
- SG&A: $6.7M (YoY +36%), due to headcount and infrastructure investments.
- R&D: -$0.9M (refunded NDA fee for ET-400).
- 2025 adjusted gross margin expected to improve to ~70% as high-margin products dominate.

**【Increlex Acquisition & Strategy】**
- Acquired in Dec 2024; U.S. run rate ~$10M at acquisition, now ~$20M post-launch.
- Target: 200+ patients (current 81) with potential $55M annual revenue.
- Label harmonization with EU could expand U.S. market to ~1,000 patients ($250M+).
- Eton Cares program offers $0 co-pay and streamlined access.

**【Galzin & Wilson Disease】**
- Acquired in Jan 2025; ~2,000 diagnosed patients, 800 on zinc therapy (mostly OTC).
- Relaunch with Eton Cares: $0 co-pay, specialty pharmacy, and education campaigns.
- ET-700 extended-release zinc aims to reduce dosing frequency and GI side effects.

**【ET-400 Launch & Pipeline】**
- PDUFA date May 28, 2025; FDA-approved oral liquid for adrenal insufficiency.
- Target: 5,000 pediatric patients, ~$50M+ annual sales.
- ET-600 (desmopressin oral solution) NDA submission planned for 2025, targeting 3,000 patients.
- ET-800 (hydrocortisone injection) for hospital market, potential $100M+.

**【Q&A Highlights】**
- Increlex patient growth: 14 new patients in 2 months, targeting 100+ by end-2025.
- ET-400 launch: minimal 2025 contribution, significant 2026+ impact.
- SG&A: ~30-40% YoY growth in 2025, moderating to low double digits post-2025.
- Label harmonization: FDA meeting mid-2025, potential 2026 approval.


Actual							-0.5	-0.23	-0.31	-0.32	0.19	-0.08	-0.24	0.04	-0.21	-0.06	-0.12	0.04	-0.1	0.18	-0.02	-0.09	-0.03	-0.12	0.02	-0.02	-0.06	-0.1	0.04	0.15
Forecast							-0.2233	-0.26	-0.2533	-0.265	0.19	-0.14	-0.135	0.05	-0.08	0.03	-0.15	0.01	-0.14	-0.09	-0.1	-0.04	-0.07	-0.07	-0.01	-0.0033	0.0533	-0.0367	0.09	0.1333
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-123.91%	+11.54%	-22.38%	-20.75%	0.00%	+42.86%	-77.78%	-20.00%	-162.50%	-300.00%	+20.00%	+300.00%	+28.57%	+300.00%	+80.00%	-125.00%	+57.14%	-71.43%	+300.00%	-506.06%	-212.57%	-172.48%	-55.56%	+12.53%

ETON

ETON fundamentals

ETON Q4 2025 Earnings

Earnings Call

You can ask Aime

ETON

ETON fundamentals

ETON Q4 2025 Earnings

Earnings Call

ETON Earnings Call Summary for Q4/20254:30 PM on Mar 19, 2026

ETON Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

ETON Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

ETON Earnings Call Summary for Q1/20254:30 PM on May 13, 2025

ETON Earnings Call Summary for Q4/202410:00 AM on Mar 18, 2025

You can ask Aime